1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Carver Biosciences

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2021

Location

Boston MA US

Primary Industry

Healthcare

About

Based in Massachusetts, US, and founded in 2021 by Walter R. Strapps (CEO), and Cameron Myhrvold (Assistant Professor), Carver Biosciences operates as a healthcare company that offers solutions for treating different viruses that affect humans. In September 2022, Carver Biosciences raised a seed round led by Khosla Ventures. Carver Biosciences created Cas13-based technology to treat patients infected with respiratory viruses. This technology provides a programmable platform for treating various existing viruses as well as quickly responding to new viruses as they emerge. The company plans to use September 2022 funding to conduct initial proof of concept Cas13 experiments in cells and in models of disease at their laboratories in Boston and with CRO partners.
Current Investors
Khosla Ventures

Request a demo to show more

Primary Industry
Healthcare
Sub Industries
Biopharmaceuticals, Healthcare, Healthcare IT
Website
www.carver.bio
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.